<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394056</url>
  </required_header>
  <id_info>
    <org_study_id>NKP106254</org_study_id>
    <nct_id>NCT00394056</nct_id>
  </id_info>
  <brief_title>Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.</brief_title>
  <official_title>Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus &amp; Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tinnitus associated to hearing loss is a high prevalent audiologic disorder with important
      unmet needs as far as therapy is concerned. The present study is exploring the possible
      beneficial effects on tinnitus loudness or annoyance of a combination drug treatment aimed to
      increase the local inhibitory activity of neural circuitries involved in sound perception and
      generation. Modest effects have been reported after 8-12 weeks treatment with
      antidepressants, including high dose paroxetine (up to 50 mg/day). Biologic data suggests
      that the combination of increase of extracellular serotonin using an SSRI and of blockade of
      NK1 receptors using a novel NK1 antagonist may lead to a reduced tinnitus and, possibly,
      improved hearing acuity. To this aim, two 14 day treatment conditions, i.e., SSRI paroxetine
      (20 mg/day) plus the NK1 antagonist vestipitant (25mg /day) or vestipitant alone (25 mg
      /day), will be compared to placebo in patients suffering from tinnitus previously selected
      for their capacity to reliably score the transient attenuation of tinnitus loudness produced
      by lidocaine infusion. Effects on principal endpoints will be collected within 4 hrs from
      last administration, when the plasma levels of vestipitant are calculated to be in the range
      associated to pharmacodynamic effects on VAS anxiety and qEEG (&gt;30 ng/ml). PK, safety and
      tolerability of the paroxetine-vestipitant combination was addressed with preclinical and
      Phase I studies, showing no relevant issue. The cross-over study will require approximately
      24 patients. Audiometry and computer-based Automated Psychoacoustics will be performed as
      instrumental endpoints to support subjective scores. A diary will be used at home to score
      tinnitus severity at home during the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scales (VAS) to measure the change in tinnitus loudness as perceived at the moment of the measurement at 2 hrs after dosing (or at any other time point vs. pre-dose baseline).</measure>
    <time_frame>2 hrs after dosing (or at any other time point vs. pre-dose baseline).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS to measure tinnitus pitch, distress and anxiety. Pure Tone Audiometry &amp; Psychoacoustic assessment. Sleep &amp; Tinnitus questionnaires. Safety, tolerability and pharmacokinetics of drug.</measure>
    <time_frame>perceived at the moment of the measurement at 2 hrs after dosing (or at any other time point vs. pre-dose baseline).</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vestipitant</intervention_name>
    <description>NK1 receptor antagonist</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vestipitant + Paroxetine</intervention_name>
    <description>NK1 receptor antagonist and SSRI</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <other_name>Vestipitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female subjects with a diagnosed tinnitus.

          -  Subject with THI severity grade of 3 or 4.

          -  Subjects willing to restrict alcohol intake.

          -  The subject must have given written consent.

          -  Women of childbearing potential who abstain from intercourse OR agree to birth
             control.

          -  Women of non-childbearing potential.

        Exclusion criteria:

          -  Subject with THI severity grade = 5 or less than or equal to 2.

          -  Subject with pathologic level of anxiety or depression.

          -  Subject with no audiogram deficit and with normal hearing.

          -  Subjects that do not respond to the lidocaine infusion test or show a large
             variability in pre-infusion values.

          -  Subjects with any serious medical or surgical condition

          -  Subjects positive for drug use and/or a history of substance abuse or dependence.

          -  Subjects who have taken psychotropic drugs or antidepressants within specified time
             frames.

          -  Subjects who have recently used an investigational drug or recently participated in a
             trial.

          -  Subjects who have exhibited intolerance to NK1 antagonists or SSRIs.

          -  Women who have a positive pregnancy test.

          -  Female subjects who intend to get pregnant or male subjects who intend to father a
             child within the next 4 weeks following the last study drug administration in the
             study.

          -  Subjects, who have donated a unit of blood or more within the previous month or who
             intend to donate blood within one month of completing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Roberts C, Inamdar A, Koch A, Kitchiner P, Dewit O, Merlo-Pich E, Fina P, McFerran DJ, Baguley DM. A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. Otol Neurotol. 2011 Jul;32(5):721-7. doi: 10.1097/MAO.0b013e318218a086.</citation>
    <PMID>21646935</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>placebo</keyword>
  <keyword>balanced</keyword>
  <keyword>paroxetine</keyword>
  <keyword>repeated dose</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>loudness</keyword>
  <keyword>combination</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>vestipitant (GW597599)</keyword>
  <keyword>randomised</keyword>
  <keyword>annoyance</keyword>
  <keyword>crossover</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Vestipitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKP106254</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>July 13, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 14, 2017</submitted>
    <returned>February 2, 2018</returned>
    <submitted>March 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

